Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

The Battle of the Biologics and Biosimilars Continues

XTALKS VITALS NEWS

A major patent on Humira® may expire December 2016 and there is much debate over its renewal by the patent trial and appeal board.

Tweetables from this article:

Tweet:  Humira® mimics endogenous cellular activity and reduces expression tumor necrosis factor (TNF)

Share this!

September 12, 2016 | by Kelly Daescu

The drug Humira®,produced by AbbVie Inc., specifically targets several autoimmune conditions including rheumatoid arthritis. Humira® mimics endogenous cellular activity and reduces expression tumor necrosis factor (TNF), an important regulator of inflammation. It is the top-selling drug in the world, but it comes with an expensive price tag, ranging from approximately, $20,000 to $50,000 a year.

A major patent on Humira® may expire December 2016 and there is much debate over its renewal by the patent trial and appeal board. The FDA is recommending green-lighting production of generic competitor biosimilars, and pharmaceutical giants like Amgen and Pfizer are crossing their fingers that the patent will expire since their generic versions are ready to market. Amgen, in fact, has already submitted a request to market a Humira® biosimilar to the FDA, and AbbVie responded with a lawsuit.



AbbVie says “not so fast” as they attempt to block the threat to their niche. They tout Amgen as a hypocrite, for Amgen staunchly defended its own biologic called Neupogen® and fought Novartis’ biosimilar Zarxio from being approved. Amgen defended its own biologic exclusivity by citing the difficulty involved with production, manufacturing, and distribution of such innovative and complex substances. The tables have turned as Humira® fights Amgen’s for similar reasons. Indeed, research and development for making such targeted, advanced treatment costs billions of dollars.

The competing drug companies producing the generic alternatives are resting on the Biologics Price Competition and Innovation Act (BPCIA) that was passed in 2010 to facilitate development of biosimilars. This year, there has been another proposal called the Price Relief, Innovation and Competition for Essential Drugs (PRICED) Act. It piggybacks on the BPCIA by proposing the previous 12-year biologic exclusivity previously granted be limited to only 7 years.

No matter how the battle between AbbVie and its competitors turn out, this kind of innovative technology will continue to improve. Europe has had biosimilars available for ten years, and no matter how much industry fights it, with the potential patent expiry of the world’s top-selling drug, it appears that more and more biosimilars may become available in the U.S in the near future.


Keywords: Humira, FDA, Biosimilars


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News


Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News


Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Electronic Informed Consent: 2017 Industry Survey Results


Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time


The Modernization of eCOA Technology for Clinical Trials


Developing a Biological Safety Evaluation


Copyright © 2016-2017 Honeycomb Worldwide Inc.